Licensable university IP
Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease
Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease is marketed for licensing by University of California. It is documented in US patent US 9,072,732. The current assignee of record is Kamanna Shobha V. Google Patents reports its legal status as “Active” (an automated indicator, not a legal determination). Its expected expiration is 2031-11-22.
The patent's current assignee of record differs from the marketing institution (University of California). Confirm licensing rights with the assignee of record before relying on this listing.
Patent picture
| Field | Value | Reliability | Source |
|---|---|---|---|
| US patent | US 9,072,732 | High | Google Patents |
| Patent title | Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease | High | Google Patents |
| Current assignee | Kamanna Shobha V | Good | Google Patents |
| Original assignee | US Department of Veterans Affairs | Good | Google Patents |
| Legal status | Active | Moderate | Google Patents |
| Filing date | 2011-11-22 | High | Google Patents |
| Priority date | 2010-11-22 | High | Google Patents |
| Publication date | 2015-07-07 | High | Google Patents |
| Expected expiration | 2031-11-22 | Moderate | Google Patents |
- High 90% and up
- Good 80 to 89%
- Moderate 70 to 79%
Legal status is Google Patents' automated indicator, not a legal determination.
Joined to US 9,072,732 by its printed patent number (a deterministic match), then enriched from public Google Patents data. Fields are shown only where resolved against a public source; unresolved fields are omitted, never guessed.
Grouped under Biotechnology & Life Sciences · Materials & Chemistry, derived from its patent classification (CPC A61K, C07D; Google Patents).
Original listing
This technology is marketed for licensing by University of California. View the original listing.